This presentation includes forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995. Any statements, other than statements of historical fact, including our financial guidance

Aptevo Therapeutics Investor

Presentation January 2018 Exhibit 99.1

This presentation includes

forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995. Any statements, other than statements of historical fact, including our financial guidance, product portfolio, product sales, capabilities and any

other statements containing the words "believes", "expects", "anticipates", "intends", "plans", "forecasts", "estimates" and similar expressions in conjunction with,

among other things, discussions of financial performance or financial condition, growth strategy, product sales, manufacturing capabilities, product development, regulatory approvals or expenditures are forward-looking statements. These

forward-looking statements are based on our current intentions, beliefs and expectations regarding future events. We cannot guarantee that any forward-looking statement will be accurate. Investors should realize that if underlying assumptions prove

inaccurate or unknown risks or uncertainties materialize, actual results could differ materially from our expectations. Investors are, therefore, cautioned not to place undue reliance on any forward-looking statement. Any forward-looking statement

speaks only as of the date of this presentation, and, except as required by law, we do not undertake to update any forward-looking statement to reflect new information, events or circumstances. There are a number of important factors that could

cause Aptevo's actual results to differ materially from those indicated by such forward-looking statements, including possible negative effects on Aptevo's business operations, assets or financial results as a result of the separation; a

deterioration in the business or prospects of Aptevo; adverse developments in Aptevo's customer-base or markets; our ability to enter into and maintain selective collaboration and partnership arrangements; the timing of and our ability to

achieve milestones in collaboration and partnership contracts; our ability and the ability of our contractors and suppliers to maintain compliance with cGMP and other regulatory obligations; the results of regulatory inspections; the rate and degree

of market acceptance and clinical utility of our products; the success of our ongoing and planned development programs; the timing of and our ability to obtain and maintain regulatory approvals for our product candidates; and our commercialization,

marketing and manufacturing capabilities and strategy and changes in regulatory, social and political conditions. Additional risks and factors that may affect results are set forth in our filings with the Securities and Exchange Commission,

including Aptevo's most recent Annual Report on Form 10-K, as filed on March 31, 2017, and its subsequent reports on Form 10-Q and current reports on Form 8-K The foregoing sets forth many, but not all, of the factors that could cause actual

results to differ from our expectations in any forward-looking statement. Investors should consider this cautionary statement, as well as the risk factors identified in our periodic reports filed with the SEC, when evaluating our forward-looking

statements. Aptevo , ADAPTIR and any and all Aptevo Therapeutics Inc. brand, product, service, and feature names, logos, and slogans are trademarks or registered trademarks of Aptevo Therapeutics Inc. or its subsidiaries in the United States

Aptevo: At a Glance Leading Oncology

Platform Innovative ADAPTIR platform technology utilizing a novel approach in the highly attractive immuno-oncology field Leveraging Technology Targeted investments in bispecific ADAPTIR therapeutics Robust IP Estate Own and exclusively licensed

patents and trade secrets which support our commercial product and pipeline Focus Oncology/Hematology Commercial Product IXINITY Product Pipeline Clinical: 2 Preclinical: Multiple Platform Technology ADAPTIR Employees ~120 Headquarters

Seattle, WA IXINITY Revenue 2017 (9/30/17) $8.1M 2016 $9.8M 2015 $1.0M Cash Position $91M (12/31/2017)

Aptevo - A Compelling Investment

Opportunity Solid cash position to advance R&D and commercial strategy 1 2 3 4 5 Strong leadership with a track record of execution Advancing ADAPTIR to generate novel first-in-class therapeutics Broad pipeline of wholly-owned clinical and

preclinical candidates Commercial asset (IXINITY) with growth potential

Agenda Executing on our Strategy

ADAPTIR - Developing Novel Protein Therapeutics Impressive Clinical and Preclinical Portfolio IXINITY - A Growing Commercial Opportunity Summary

Experienced Leadership Team Senior

Management Marvin White - President & CEO Former Emergent Director; Former CFO, St. Vincent's Health; Former Exec. Director & CFO, Lilly USA Jeff Lamothe - SVP, CFO Former Emergent VP, Finance; Former CFO, Cangene

Corporation Randy Maddux - SVP, Operations Former VP, Global Mfg & Supply, GSK; Former VP, Mfg Ops & Quality, Human Genome Sciences Dr. Scott Stromatt - SVP, CMO Former Emergent SVP, CMO; Former CMO, Trubion Dr. Jane Gross

- SVP, CSO Former Emergent VP, Research/Non-Clinical Development; Former VP Immunology Research ZymoGenetics Inc. Mike Adelman - VP, Commercial Ops. Former Emergent VP, Commercial Operations; Former, VP Commercial Operations, Cangene

Corporation Shawnte Mitchell - VP, Gen'l Counsel/HR Former Emergent VP, Associate General Counsel Board of Directors Marvin White Former Emergent Director; Former CFO, St. Vincent's Health; Former Exec. Director & CFO, Lilly

USA Fuad El-Hibri Founder, Executive Chairman, Emergent BioSolutions Daniel Abdun-Nabi President & CEO, Emergent BioSolutions Grady Grant, III Reckitt Benckiser Group (formerly Mead Johnson Nutrition); Eli Lilly & Co. Zsolt Harsanyi, Ph.D.

N-Gene Research Labs; Exponential Biotherapies; Porton Int'l Barbara Lopez Kunz DIA; Battelle; Thermo Fisher Scientific; ICI/Uniqema John Niederhuber, M.D. Inova Translational Medicine Institute; NCI; Johns Hopkins Univ. Deep R&D,

Manufacturing, Commercial and Financial Expertise and Experience

Executing on our Strategy to Build

Value Objective Result Solidly capitalize Aptevo to advance R&D and commercial programs Obtained: $65M in start-up funding from Emergent $20M in debt financing from MidCap $75M commercial asset sale Cash balance: $91M (12/31/2017) Build

proprietary ADAPTIR bispecific platform and rapidly advance candidates towards the clinic Advanced APVO414 in Phase 1 development Positioned APVO436 for Q2:18 IND submission Positioned APVO210 for Q4:18 IND submission Demonstrate ADAPTIR versatility

by developing ADAPTIR bispecifics with new mechanisms of action (MOA) Executed co-development agreement with Alligator Bioscience for 4-1BB x 5T4 immunotherapeutic for solid tumors Advanced APVO210 with different MOA focusing on targeted cytokine

delivery for autoimmune and inflammatory diseases (AIID) Develop second generation ADAPTIR platform with antibody-like characteristics Demonstrated 12.5 day/3.5 day serum half life in rodents/non-human primates (APVO436) Optimized manufacturing

process; able to produce cell culture yields greater than 1.5 g/L; sufficient for clinical and commercial production

Product/Candidate Target Technology

Indication Pre-Clinical Clinical Development Stage Marketed Milestones/Highlights Phase I Phase II Phase III COMMERCIAL PORTFOLIIO IXINITY Recombinant Protein Hemophilia B $8.1M (9/30/17) $9.8M (2016) $1.0M (2015) ADAPTIR PORTFOLIO Otlertuzumab CD37

ADAPTIR Monospecific PTCL/CLL Executing Phase 2 combination study in PTCL APVO414 CD3/PSMA ADAPTIR Bispecific RTCC mCRPC Immuno-oncology Executing Phase 1 dose escalation study; Cohort 6 APVO436 CD3/CD123 ADAPTIR Bispecific RTCC AML IND filing Q2

2018 APVO210 IL10/CD86 ADAPTIR Targeted Cytokine Autoimmune & Inflammatory Diseases IND filing Q4 2018 ALG.APV-527* 4-1BB/5T4 ADAPTIR Bispecific T-cell Co-stimulation Multiple Solid Tumors CMC & IND-enabling activities; CTA in 2019 ROR1

ADAPTIR Bispecific RTCC / New MOA Hematologic and Solid Tumors POC in vitro/in vivo; lead candidate in development Multiple ADAPTIR candidates ADAPTIR Bispecific RTCC / New MOA Hematologic and Solid Tumors Evaluating RTCC candidates with novel MOA

Robust and Diversified Product Portfolio * Partnered with Alligator Bioscience RTCC - Redirected T-Cell Cytotoxicity = T-Cell Engager

Agenda Executing On Our Strategy

ADAPTIR - Developing Novel Protein Therapeutics Impressive Clinical and Preclinical Portfolio IXINITY - A Growing Commercial Opportunity Summary

ADAPTIR is Aptevo's platform

technology for generating novel monospecific and bispecific antibody therapeutics for immuno-oncology and autoimmune/inflammatory diseases ADAPTIR is a robust, flexible platform that can be used to generate bispecific molecules with different

mechanisms of action The ADAPTIR platform and structure provides distinct advantages over other bispecific technologies and therapeutic approaches Advancing ADAPTIR Technology to Generate Novel First-In-Class Therapeutics

Key Advantages of ADAPTIR

Bispecifics* ADAPTIR Bispecifics Unique homodimer structure Longer half-life Enhanced stability Bivalent binding for improved potency Better manufacturability Increased flexibility *Based on current

preclinical data for various ADAPTIR candidates

Platform produces drugs with

multiple mechanisms to stimulate the body's own immune system for the treatment of autoimmune diseases and cancer ADAPTIR - A Versatile Therapeutic Platform T-cell Engagers CD3 + Tumor Antigen T-cell Co-stimulators + Tumor Antigen (e.g.

4-1BB) Targeted Cytokines IL-10 AIID/Oncology Oncology Oncology Cytokine Targeting Arm Costimulatory Receptor T cell Activating an existing anti-Tumor Response T cell TCR/CD3 TCR/CD3 Immune Cell Suppress Autoimmunity Inflammation Tumor Killing

Bispecific ADAPTIR Therapeutic

Anti-tumor Anti-CD3 * MOR209/ES414, A Novel Bispecific Antibody Targeting PSMA For The Treatment of Metastatic Castration-Resistant Prostate Cancer, Hernandez-Hoyos et al. Molecular Cancer Therapeutics, July 12

2016 DOI: 10.1158/1535-7163.MCT-15-0242 Unique Features of ADAPTIR Bispecific T-Cell Engagers Novel, proprietary humanized binding domain targeting CD3 Increased T-cell engagement and tumor killing compared to monovalent bispecifics T-cell

stimulation results in reduced cytokine release upon T-cell activation* Traditional antibody-like manufacturability and half-life

ADAPTIR RTCC molecules have more

potent tumor killing compared to heterodimer formats targeting the same tumor antigen Lower concentrations (EC50) needed to achieve same potency in Tumor Lysis Assays ADAPTIR - More Potent than Heterodimer Bispecifics Targeting Same Antigen ADAPTIR

T cell Tumor cell lysis ADAPTIR More Potent Lower EC50 * 17 pM 67 pM 136 pM EC50

ADAPTIR RTCC Candidates Induce Lower

Levels of Cytokines than Competitor scFv-scFv Formats Cytokines measured after 20 hr stimulation of T cells with ADAPTIR and tumor cells ADAPTIR bispecifics generate lower levels of cytokines when tumor antigen present compared to other formats

(scFv-scFv) targeting the same tumor antigen scFv-scFv ADAPTIR Tumor Target T cell activation cytokine release

Agenda Executing On Our Strategy

ADAPTIR - Developing Novel Protein Therapeutics Impressive Clinical and Preclinical Portfolio IXINITY - A Growing Commercial Opportunity Summary

Product Candidate Technology

Indication Target Pre-Clinical Clinical Development Stage Milestones/Highlights Phase I Phase II Phase III Otlertuzumab ADAPTIR Monospecific PTCL/CLL CD37 Executing Phase 2 combination study in PTCL APVO414 ADAPTIR Bispecific RTCC mCRPC CD3/PSMA

Executing Phase 1 dose escalation clinical trial; Cohort 6 APVO436 ADAPTIR Bispecific RTCC AML CD3/CD123 Initiated CMC and IND-enabling activities; IND filing Q2 2018 APVO210 ADAPTIR Targeted cytokine IBD IL10/CD86 Initiated CMC and IND-enabling

activities; IND filing Q4 2018 ALG.APV-527 * ADAPTIR Bispecific T-cell Co-Stimulation Multiple Solid Tumors 41BB/Tumor Antigen Initiated CMC and IND-Enabling Activities; CTA in 2019 ROR1 ADAPTIR Bispecific RTCC / New MOA Heme/Onc & Solid Tumors

ROR1 POC in vitro and in vivo; lead candidate in development ADAPTIR Candidate 1 RTCC / and New MOA Heme/Onc & Solid Tumors Undisclosed Tumor Antigen Evaluating RTCC candidates with novel MOA ADAPTIR Candidate 2 RTCC / and New MOA Heme/Onc &

Solid Tumors Undisclosed Tumor Antigen Evaluating RTCC candidates with novel MOA ADAPTIR Candidate 3 RTCC / and New MOA Heme/Onc & Solid Tumors Undisclosed Tumor Antigen Evaluating RTCC candidates with novel MOA ADAPTIR Portfolio Snapshot

*Partnered with Alligator Bioscience RTCC - Redirected T-Cell Cytotoxicity = T-Cell Engager

Otlertuzumab - Clinical

Candidate CANDIDATE OPPORTUNITY FUNCTION/ MOA INDICATIONS DEVELOPMENT STAGE PARTNERSHIP STATUS aCD37 scFv Human IgG1 Fc ADAPTIR monospecific antibody Targets CD37 Direct apoptosis, antibody-dependent cell cytotoxicity PTCL - Peripheral T-Cell

Lymphoma (PTCL) CLL - Chronic Lymphocytic Leukemia NHL - Non-Hodgkin Lymphoma > 250 subjects treated to date Clinical POC published in CLL Demonstrates increased ORR/PFS in CLL in combination with bendamustine Phase 2 initiated in

PTCL Wholly owned by Aptevo

Otlertuzumab + Bendamustine

Significantly Increased Overall Response Rate Overall Response Complete Response Partial Response Stable Disease Progressive Disease Percent Response 100% 80% 60% 40% 20% 0% 69% 39% 59% 9% 3% 36% 16% 30% 16% 30% p = 0.026

5 month difference in PFS

Otlertuzumab + Bendamustine Significantly Increased Progression Free Survival p = 0.019 0 5 10 15 20 25 0 20 40 60 80 100 Months Since Randomization Progression Free Survival (%) Otlertuzumab +Bendamustine Bendamustine

APVO414 - Clinical Candidate

CANDIDATE OPPORTUNITY FUNCTION/MOA INDICATIONS DEVELOPMENT STAGE PARTNERSHIP STATUS Bispecific protein therapeutic targeting prostate specific membrane antigen (PSMA) & CD3 Demonstrates redirection of T-cells to kill tumor cells expressing PSMA

in vitro and in vivo Metastatic castration-resistant prostate cancer (mCRPC) Open-label Phase 1 continuous infusion study underway (Stage 1) Objectives: MTD, tolerability, PK, PD, immunogenicity, cytokine response, clinical activity Wholly owned by

Currently in Cohort 6 Well

tolerated; enrollment continues Amended study with Continuous Infusion to reduce Anti-Drug Antibody (ADA) Clinical data with other drugs suggests continuous exposure desensitizes immune system and reduces ADA Dramatic reduction in ADA with

continuous infusion; 1,000 fold reduction Titers reduced from 1:250,000 to 1:350 Dose escalation ongoing to define MTD Clinical measurements: PSA, tumor size by CT scan, circulating tumor cells Data expected end of 2018 Modified ADAPTIR bispecific

platform to eliminate ADA in Next Generation ADAPTIR candidates APVO414 Phase 1 Dose Escalation for mCRPC

APVO436 - Preclinical

Candidate CANDIDATE OPPORTUNITY FUNCTION/MOA INDICATIONS DEVELOPMENT STAGE PARTNERSHIP STATUS CD123 x CD3 bispecific candidate Engages T cell via binding to CD3 to specifically kill tumor cells expressing CD123 Targets multiple hematological

malignancies AML, ALL, hairy cell leukemia, myelodysplastic syndrome CMC and IND-enabling activities underway IND Filing Q2:18 Wholly owned by Aptevo aCD3 scFv aCD123 scFv

Addition of healthy donor T cells

increased cytotoxicity in a E:T-dependent manner Significant cytotoxicity achieved even at the lowest levels of blast CD123 expression No consistent linear relationship between the level of blast CD123 expression and cytotoxicity APVO436 Activity

with Newly Diagnosed or Relapsed/Refractory AML Patient Samples* AML Sample Cytotoxicity at 48 hrs

Treatment of established

disseminated MOLM-13 tumors in mice with APVO436 resulted in rapid reduction in skeletal tumor burden APVO436 Eliminates Skeletal Tumor Burden in Mice with Established Tumors Day 15 T cells + APVO436 (d4) T cells + APVO436 (d5) T cells only (d4) NSG

mice implanted IV with MOLM-13 cells on day 0 T cells implanted on day 4 Remaining tumor burden in non-skeletal location